Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAD study of liraglutide in Alzheimer's disease
ISRCTN89711766Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Dec 2013
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Victoza with Placebo (2 arms). Primary endpoint: Change in cerebral glucose metabolic rate. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ISRCTN89711766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89711766.